

Conatus Pharmaceuticals Inc.  
Form 8-K  
June 04, 2015

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

---

FORM 8-K

---

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 29, 2015

---

CONATUS PHARMACEUTICALS INC.  
(Exact Name of Registrant as Specified in its Charter)

---

Delaware  
(State or Other Jurisdiction  
of Incorporation)

001-36003  
(Commission  
File Number)

20-3183915  
(IRS Employer  
Identification No.)

16745 West Bernardo Drive, Suite 200  
San Diego, CA  
(Address of Principal Executive Offices)

92127  
(Zip Code)

Registrant's telephone number, including area code: (858) 376-2600

(Former Name or Former Address, if Changed Since Last Report.)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Item 1.01 Entry into a Material Definitive Agreement.

On May 29, 2015, Conatus Pharmaceuticals Inc. (the “Company”) entered into a first amendment to the lease agreement for its corporate office space with The Point Office Partners, LLC (the “First Amendment”). Under the terms of the First Amendment, the Company will lease an additional 3,271 square feet for a total of approximately 13,225 square feet of office space from September 1, 2015 through September 30, 2020. The monthly base rent will increase annually by approximately 3% from approximately \$32,784 in 2015 to \$39,268 in 2020. The Company will be entitled to a one-time tenant improvement allowance of up to \$65,420.

The foregoing description of the First Amendment does not purport to be complete and is qualified in its entirety by the First Amendment, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by this reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

| Exhibit No. | Description   |
|-------------|---|
| 10.1        | First Amendment to Lease Agreement dated May 29, 2015 by and between the Point Office Partners, LLC and the Company |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 4, 2015

CONATUS PHARMACEUTICALS INC.

|        |  |
|--------|--|
| By:    | /s/ Charles J. Cashion   |
| Name:  | Charles J. Cashion   |
| Title: | Senior Vice President, Finance,<br>Chief Financial Officer and Secretary |